• Profile
Close

Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis

American Journal of Ophthalmology Sep 09, 2017

Sepah YJ, et al. - A randomized, controlled, multicenter clinical trial is carried out to report the primary end-point analyses of the safety and effectiveness of two different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with non-infectious intermediate, posterior or pan-uveitis. Based on these outcomes, repeated IV administrations of TCZ are well tolerated. TCZ (both 4 and 8 mg/kg) is successful in improving visual acuity (VA) and decreasing VH and central macular thickness (CMT) in eyes with non-infectious intermediate, posterior and pan-uveitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay